Elicio Therapeutics Inc.
Organization details
- Legal name
- Elicio Therapeutics Inc.
- Former names
- Angion Biomedica Corp.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ELTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001601485
- EIN
- 11-3430072
Board of directors
-
Allen Nissenson · DirectorSince 2023
-
Assaf Segal · DirectorSince 2023
-
Carol Gail Ashe · DirectorSince 2023
-
Jay Venkatesan · DirectorSince 2023
-
Julian Adams · DirectorSince 2023
-
Karen J. Wilson · DirectorSince 2023
-
Robert Connelly · Director · CEO, President and DirectorSince 2023
-
Robert R. Ruffolo · DirectorSince 2023
-
Yekaterina Chudnovsky · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 19, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.3%
Board connections
5 of this board's directors also sit on 5 other boards. 5 are in the same sector.
-
Serina Therapeutics Inc. Same sectorvia Jay Venkatesan and Karen J. Wilson
-
Connect Biopharma Holdings Limited Same sectorvia Karen J. Wilson
-
Immix Biopharma Inc. Same sectorvia Yekaterina Chudnovsky
-
LB Pharmaceuticals Inc Same sectorvia Robert R. Ruffolo
-
Rockwell Medical Inc. Same sectorvia Allen Nissenson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 2, 2026 | Robert Connelly Director, Officer (CEO, President and Director) | Grant or award | +73,600 | — | — |
| Feb 2, 2026 | Shah Preetam Officer (See Remarks) | Grant or award | +24,000 | — | — |
| Feb 2, 2026 | DeMuth Peter Officer (Chief Scientific Officer) | Grant or award | +20,800 | — | — |
| Feb 2, 2026 | Haqq Christopher Officer (See Remarks) | Grant or award | +25,400 | — | — |
| Dec 9, 2025 | DeMuth Peter Officer (Chief Scientific Officer) | Option exercise | +362 | $4.41 | $1,596 |
| Mar 5, 2025 | Yekaterina Chudnovsky Director, 10% owner | Derivative conversion | +3,500,573 | $5.81 | $20,338,329 |
| Dec 16, 2024 | DeMuth Peter Officer (Chief Scientific Officer) | Option exercise | +381 | $4.41 | $1,680 |
| Nov 26, 2024 | Jay Venkatesan Director | In-the-money exercise | +50,000 | $0.01 | $500 |
| Dec 22, 2023 | Yekaterina Chudnovsky Director, 10% owner | Open-market purchase | +1,213,000 | $5.81 | $7,047,530 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Elicio Therapeutics Inc.
Who is the CEO of Elicio Therapeutics Inc.?
Robert Connelly has been Elicio Therapeutics Inc.'s CEO, President and Director since June 2023.
How many directors are on Elicio Therapeutics Inc.'s board?
Elicio Therapeutics Inc.'s board has 9 directors: Allen Nissenson, Assaf Segal, Carol Gail Ashe, Jay Venkatesan, Julian Adams, Karen J. Wilson, Robert Connelly, Robert R. Ruffolo and Yekaterina Chudnovsky.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="elicio-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.